We are aware of recent media reports that long-term use of bisphosphonates for osteoporosis (sold under the names of Fosamax [alendronate] and Actonel [risedronate]) may be associated with the occurrence […]

We are aware of recent media reports that long-term use of bisphosphonates for osteoporosis (sold under the names of Fosamax [alendronate] and Actonel [risedronate]) may be associated with the occurrence […]

Osteoporosis Canada’s overall position statement in response to this study: This study did not specifically address the vitamin D requirements of individuals with osteoporosis, those with risk factors for osteoporotic […]

Denosumab (Prolia) has been shown to reduce the risk of fracture in postmenopausal women and men ≥50 years old with osteoporosis. It has also been approved for steroid induced bone […]

We are aware of a recent Food and Drug Administration (FDA) publication that reports on the association between use of zoledronic acid (Aclasta) and renal impairment. 1 We recognize that […]

The recent study by Bolland and colleagues published in the Lancet Diabetes Endocrinology (Oct 4, 2018) is an updated meta-analysis that evaluated the effects of vitamin D supplementation on fractures, […]

Contributors: Dr. Adrian Lau, Dr. Claudia Gagnon, Dr. Laëtitia Michou, Dr. Emma Billington, Dr. Zahra Bardai, Dr. Dr. Vithika Sivabalasundaram, Dr. Rowena Ridout, Dr. Sandra Kim, Dr. Suzanne Morin Recommendations […]

There is no excerpt because this is a protected post.

VIDEO SERIES ON EXERCISE AND OSTEOPOROSIS Osteoporosis Canada has developed a video series on exercise and osteoporosis in partnership with the University of Waterloo and Geriatric Education and Research in […]